Study on the Effect of Regorafenib Combined with PD-1 Antibody in the Treatment of Liver Cancer
Objective:To investigate the clinical application value of regorafenib combined with PD-1 antibody in inhibiting the growth of cancer cells in patients with liver cancer.Methods:A total of 120 patients with liver cancer who were treated in our hospital from July 2019 to July 2020 were selected as the research objects.According to the random number table method,they were divided into observation group and control group,with 60 patients in each group.The control group was treated with regorafenib,and the observation group was treated with PD-1 on the basis of the control group.The clinical efficacy,adverse reactions and immune function indexes of the two groups were compared.Results:The total effective rate of treatment in the observation group was 78.33%,which was higher than 63.33%in the control group(P<0.05).The incidence of adverse reactions in the observation group was 11.67%,which was lower than 21.67%in the control group(P<0.05).After treatment,CD4+and CD4+/CD8+in the two groups were higher than those before treatment,CD8+was lower than that before treatment,and CD4+and CD4+/CD8+in the observation group were higher than those in the control group,CD8+was lower than that in the control group(P<0.05).Conclusion:Regorafenib combined with PD-1 antibody has a significant clinical effect in inhibiting the growth of cancer cells in patients with liver cancer.It can not only effectively improve the immune function of patients,but also reduce the adverse reactions of patients.
NETL
NSTL
万方数据
